Evidence map›Paper›PMID 42169144›Full record

ArticleCell communication and signaling : CCS2026

Fibroblast growth factor receptor substrate 2 interactome mapping reveals novel candidate interactors associated with migration and invasion.

Levi Luca Kopp, Dejana Versamento, Bernard Ciraulo, Marc Thomas Schönholzer, Dina Hochuli, Meng-Syuan Lin, Martin Baumgartner

Abstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Levi Luca KoppPediatric Molecular Neuro-Oncology Research, Division of Oncology and Children's Research Center, University Children's Hospital Zürich, August-Forel Strasse 51, Zürich, 8008, Switzerland.
Dejana VersamentoPediatric Molecular Neuro-Oncology Research, Division of Oncology and Children's Research Center, University Children's Hospital Zürich, August-Forel Strasse 51, Zürich, 8008, Switzerland.
Bernard CirauloPediatric Molecular Neuro-Oncology Research, Division of Oncology and Children's Research Center, University Children's Hospital Zürich, August-Forel Strasse 51, Zürich, 8008, Switzerland.
Marc Thomas SchönholzerPediatric Molecular Neuro-Oncology Research, Division of Oncology and Children's Research Center, University Children's Hospital Zürich, August-Forel Strasse 51, Zürich, 8008, Switzerland.
Dina HochuliPediatric Molecular Neuro-Oncology Research, Division of Oncology and Children's Research Center, University Children's Hospital Zürich, August-Forel Strasse 51, Zürich, 8008, Switzerland.
Meng-Syuan LinPediatric Molecular Neuro-Oncology Research, Division of Oncology and Children's Research Center, University Children's Hospital Zürich, August-Forel Strasse 51, Zürich, 8008, Switzerland.
Martin BaumgartnerPediatric Molecular Neuro-Oncology Research, Division of Oncology and Children's Research Center, University Children's Hospital Zürich, August-Forel Strasse 51, Zürich, 8008, Switzerland. martin.baumgartner@kispi.uzh.ch.

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung CRSII5_202245/1
6 · The paper itself

Abstract

The scaffold protein FRS2 is central to FGFR signaling, linking receptor activation to MAPK/ERK and PI3K/AKT pathways. Elevated FRS2 expression correlates with aggressive tumor phenotypes and poor prognosis across multiple cancers, including the pediatric cerebellar tumor medulloblastoma (MB).Here, we characterized FRS2's subcellular localization and interactome in MB cells, employing live-cell imaging, phosphoproteomics, immunoprecipitation, and APEX2-based proximity labeling. We found that increased FRS2 expression is associated with increased motile and invasive behavior in MB tumor cells. We furthermore identified novel candidate FRS2-associated proteins involved in actin cytoskeleton remodeling, cell junction assembly, and translation initiation, which indicate a growth factor-dependent reorganization of the FRS2 signalosome. Our data additionally indicate a regulatory role of FRS2 in directing subcellular distribution of the cell junction and cell motility regulator TJP1.Our findings highlight the relevance of FRS2 as a mediator of cell motility and invasiveness and provide candidate proteins associated with FRS2 that are involved in cellular processes governing migration and invasion. This study thus provides a framework for exploring the FRS2 interactome as a possible target to attenuate FGFR-driven oncogenic processes with next-generation therapeutic strategies.

Indexed as

Adaptor Proteins, Signal TransducingCell MovementMedulloblastomaMembrane ProteinsProtein Interaction MappingCell Line, TumorHumansNeoplasm InvasivenessProtein BindingSignal TransductionAdaptor Proteins, Signal TransducingFRS2 protein, humanMembrane ProteinsActin cytoskeletonCell junctionsFGFR signalingFRS2 interactomeMedulloblastomaOncogenic transformation

Identifiers

PMID42169144
PMCPMC13393275

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.